Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.43 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1938543 | 0.95 | AOC2 (0.51) | AOC2ALDH1A1SMN1; SMN2NR2F2RAB9A | |
| SCHEMBL23370065 | 0.84 | AOC2 (0.55) | AOC2ALDH1A1SMN1; SMN2NR2F2RAB9A | |
| SCHEMBL30361453 | 0.84 | AOC2 (0.55) | AOC2ALDH1A1SMN1; SMN2NR2F2RAB9A | |
| SCHEMBL8643198 | 0.84 | AOC2 (0.55) | AOC2ALDH1A1SMN1; SMN2NR2F2RAB9A | |
| SCHEMBL28170343 | 0.84 | AOC2 (0.51) | AOC2ALDH1A1SMN1; SMN2NR2F2RAB9A | |
| SCHEMBL4961361 | 0.80 | AOC2 (0.51) | AOC2ALDH1A1SMN1; SMN2NR2F2RAB9A | |
| SCHEMBL3079952 | 0.78 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2NR2F2RAB9ALMNA | |
| SCHEMBL22289434 | 0.76 | PLCG1 (0.55) | ALDH1A1SMN1; SMN2RAB9AMEN1MAPT | |
| SCHEMBL2413925 | 0.76 | PLCG1 (0.59) | AOC2KMT2APLCG1POLBHTT | |
| SCHEMBL3077497 | 0.76 | MAPK1 (0.58) | ALDH1A1SMN1; SMN2NR2F2RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465728-B2 | Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity | ASTRAZENECA AB (SE) | 2008-12-16 | — | — | US | disclosed |
| US-20050131000-A1 | Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131000-A1 | Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity | CCNI, CDK2, CDK1 | AOC2 4357/4885ALDH1A1 1079/4885SMN1; SMN2 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.